🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

Recruitingn/aAges any - anyAllHerlev and Gentofte Hospital
NCT07623473 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit * Having signed informed consent Exclusion Criteria: * Active cancer, excluding non-melanoma skin cancer * Comorbidities that exclude the patient from clinical follow-up and final diagnosis
💊

What it tests

  • Blood tests
📍

Where

1 site
Gentofte Hospital
Gentofte Municipality, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy